Frits van Rhee

List of Publications by Year
in descending order

265 papers	8,719 citations	71102 41 h-index	46799 89 g-index
267 all docs	267 docs citations	267 times ranked	7494 citing authors

#	Article	IF	Citations
1	Nearly 70 years later: the continued unraveling of Castleman disease. Haematologica, 2023, 108, 7-8.	3.5	1
2	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, 2022, 36, 591-595.	7.2	6
3	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	5.2	14
4	Idiopathic multicentric Castleman disease treated with siltuximab for 15â€‰years: a case report. Therapeutic Advances in Hematology, 2022, 13, 204062072210825.	2.5	4
5	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	4.1	0
6	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of Clinical Medicine, 2022, 11, 1640.	2.4	6
7	Firstâ€•versus secondâ€generation Bruton tyrosine kinase inhibitors in WaldenstrÃ¶m's Macroglobulinemia: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, 942-950.	4.1	5
8	Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research, 2022, 32, 1343-1354.	5.5	8
9	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€“T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	5.9	22
10	Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis. EJHaem, 2022, 3, 748-753.	1.0	1
11	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	7.0	6
12	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	4.1	4
13	The disease course of Castleman disease patients with fatal outcomes in the <scp>ACCELERATE</scp> registry. British Journal of Haematology, 2022, , .	2.5	2
14	Chimeric Antigen Receptor T-Cell Therapy in Multiple Myelomaâ€”Challenges and Potential Solutions. JAMA Oncology, 2022, 8, 823.	7.1	6
15	Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing.. Journal of Clinical Oncology, 2022, 40, e19586-e19586.	1.6	0
16	Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Advances, 2022, 6, 4773-4781.	5.2	7
17	Monitoring treatment response and disease progression in myeloma with circulating cellâ€free DNA. European Journal of Haematology, 2021, 106, 230-240.	2.2	21
18	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British Journal of Haematology, 2021, 192, e28-e31.	2.5	4

#	Article	IF	Citations
19	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	12.8	54
20	<i>Ehrlichia</i>â€induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant. Transplant Infectious Disease, 2021, 23, e13621.	1.7	4
21	Bone remineralization of lytic lesions in multiple myeloma â€“ The Arkansas experience. Bone, 2021, 146, 115876.	2.9	4
22	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, e20031-e20031.	1.6	1
23	Persistent bone marrow minimal residual disease as a â€œhighâ€riskâ€•disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	4.1	4
24	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric <scp>Castleman</scp> disease. American Journal of Hematology, 2021, 96, 1241-1252.	4.1	47
25	TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. Journal of Clinical Investigation, 2021, 131, .	8.2	10
26	Highâ€risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology, 2021, 195, 283-286.	2.5	4
27	PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine, 2021, 69, 103290.	1.8	5
28	Combinatorial treatment for unresectable unicentric Castleman disease. European Journal of Haematology, 2021, 107, 484-488.	2.2	1
29	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology, 2021, 17, 2499-2512.	2.4	11
30	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 2021, 13, 4019.	3.7	9
31	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Advances, 2021, 5, 3445-3456.	5.2	22
32	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, 106, 0-0.	3.5	2
33	Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease. Blood, 2021, 138, 2696-2696.	1.4	5
34	NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma. Blood, 2021, 138, 2671-2671.	1.4	2
35	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. Blood, 2021, 138, 2713-2713.	1.4	0
36	N-Cadherin Stabilizes Î²-Catenin and Promotes Î²-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. Blood, 2021, 138, 1572-1572.	1.4	0

#	Article	IF	Citations
37	Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma. Blood, 2021, 138, 2802-2802.	1.4	4
38	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. Blood, 2021, 138, 566-566.	1.4	4
39	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. Blood, 2021, 138, 1627-1627.	1.4	0
40	Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity. Blood, 2021, 138, 4004-4004.	1.4	0
41	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Blood, 2021, 138, 4110-4110.	1.4	1
42	Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients. Cancers, 2021, 13, 6348.	3.7	1
43	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, , .	3.5	0
44	Daratumumab in highâ€risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British Journal of Haematology, 2020, 189, 67-71.	2.5	35
45	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
46	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 108.	17.0	20
47	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	4.1	18
48	Race-Dependent Differences in Risk, Genomics, and Epsteinâ€“Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical Cancer Research, 2020, 26, 5814-5819.	7.0	4
49	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Advances, 2020, 4, 6039-6050.	5.2	94
50	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer Journal, 2020, 10, 70.	6.2	27
51	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematology,the, 2020, 7, e209-e217.	4.6	34
52	<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	7.0	37
53	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Advances, 2020, 4, 422-431.	5.2	66
54	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	6.5	18

#	Article	IF	Citations
55	Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight, 2020, 5, .	5.0	35
56	Late Relapsing Multiple Myeloma â‰¥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. Blood, 2020, 136, 11-12.	1.4	3
57	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
58	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8514-8514.	1.6	2
59	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Medicine, 2020, 17, e1003323.	8.4	33
60	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood, 2020, 136, 44-44.	1.4	2
61	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. Blood, 2020, 136, 2-2.	1.4	0
62	Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT. Blood, 2020, 136, 24-24.	1.4	0
63	CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction. Blood, 2020, 136, 21-21.	1.4	0
64	Infectious and immunological sequelae of daratumumab in multiple myeloma. British Journal of Haematology, 2019, 185, 187-189.	2.5	35
65	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal, 2019, 9, 62.	6.2	23
66	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics, 2019, 9, 4756-4763.	10.0	12
67	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS ONE, 2019, 14, e0218660.	2.5	22
68	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
69	Storming the Castle with TCP. Blood, 2019, 133, 1697-1698.	1.4	1
70	Predictors of response to antiâ€<scp>IL</scp>6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase <scp>II</scp> clinical trial data. British Journal of Haematology, 2019, 184, 232-241.	2.5	36
71	Mesenchymal stem cells gene signature in highâ€risk myeloma bone marrow linked to suppression of distinct IGFBP2â€expressing small adipocytes. British Journal of Haematology, 2019, 184, 578-593.	2.5	18
72	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockadeâ€"refractory idiopathic multicentric Castleman disease. Journal of Clinical Investigation, 2019, 129, 4451-4463.	8.2	87

#	Article	IF	Citations
73	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood, 2019, 134, 1887-1887.	1.4	12
74	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. Blood, 2019, 134, 1845-1845.	1.4	2
75	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. Blood, 2019, 134, 4333-4333.	1.4	2
76	Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease. Blood, 2019, 134, 3599-3599.	1.4	1
77	Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare. Blood, 2019, 134, 1046-1046.	1.4	5
78	Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma. Blood, 2019, 134, 4383-4383.	1.4	3
79	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. Blood, 2019, 134, 4569-4569.	1.4	4
80	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of <i>TP53</i>. Oncotarget, 2019, 10, 732-737.	1.8	13
81	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. Blood, 2019, 134, 4412-4412.	1.4	0
82	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. Blood, 2019, 134, 3309-3309.	1.4	2
83	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 508-508.	1.4	0
84	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood, 2019, 134, 4379-4379.	1.4	0
85	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. Blood, 2019, 134, 4390-4390.	1.4	0
86	Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain. Blood, 2019, 134, 1540-1540.	1.4	3
87	Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients. Blood, 2019, 134, 5638-5638.	1.4	0
88	Plasma proteomics identifies a â€˜chemokine stormâ€™ in idiopathic multicentric Castleman disease. American Journal of Hematology, 2018, 93, 902-912.	4.1	63
89	Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia, 2018, 32, 2435-2444.	7.2	26
90	Daratumumab for POEMS Syndrome. Mayo Clinic Proceedings, 2018, 93, 542-544.	3.0	26

#	Article	IF	Citations
91	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical Cancer Research, 2018, 24, 2913-2919.	7.0	30
92	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1047-1053.	3.5	47
93	Treatment of Idiopathic Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, 89-106.	2.2	49
94	Castleman Disease. Hematology/Oncology Clinics of North America, 2018, 32, xiii-xiv.	2.2	6
95	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	1.4	232
96	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood, 2018, 132, 59-66.	1.4	75
97	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer, 2018, 18, 724.	2.6	26
98	Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Diagnostic Pathology, 2018, 13, 15.	2.0	5
99	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood, 2018, 132, 110-110.	1.4	1
100	Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies. Blood, 2018, 132, 1882-1882.	1.4	3
101	The Mutational Landscape of Primary Plasma Cell Leukemia. Blood, 2018, 132, 114-114.	1.4	2
102	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. Blood, 2018, 132, 408-408.	1.4	3
103	Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center. Blood, 2018, 132, 3701-3701.	1.4	1
104	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. Blood, 2018, 132, 4457-4457.	1.4	0
105	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. Blood, 2018, 132, 4441-4441.	1.4	0
106	Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time. Blood, 2018, 132, 3168-3168.	1.4	0
107	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. Blood, 2018, 132, 4465-4465.	1.4	1
108	Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization. Blood, 2018, 132, 2415-2415.	1.4	1

#	Article	IF	Citations
109	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. Blood, 2018, 132, 4468-4468.	1.4	0
110	Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease. Blood, 2018, 132, 3716-3716.	1.4	0
111	Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. Blood, 2018, 132, 4456-4456.	1.4	0
112	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. Blood, 2018, 132, 3185-3185.	1.4	0
113	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. Blood, 2018, 132, 1906-1906.	1.4	1
114	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. Blood, 2018, 132, 4471-4471.	1.4	0
115	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. Blood, 2018, 132, 4448-4448.	1.4	0
116	Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma. Blood, 2018, 132, 3166-3166.	1.4	0
117	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. Blood, 2018, 132, 4489-4489.	1.4	1
118	Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma. Blood, 2018, 132, 4466-4466.	1.4	0
119	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. Blood, 2018, 132, 1929-1929.	1.4	0
120	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	1.4	381
121	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.	2.8	9
122	Immunologic approaches for the treatment of multiple myeloma. Cancer Treatment Reviews, 2017, 55, 190-199.	7.7	46
123	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.	3.5	26
124	The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma. Haematologica, 2017, 102, e364-e367.	3.5	57
125	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American Journal of Hematology, 2017, 92, 739-745.	4.1	36
126	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	7.0	13

#	Article	IF	Citations
127	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research, 2017, 23, 1981-1987.	7.0	97
128	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
129	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood, 2016, 128, 2919-2930.	1.4	57
130	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood, 2016, 128, 1735-1744.	1.4	170
131	Transplantation for Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 227-250.	0.5	2
132	Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematology,the, 2016, 3, e163-e175.	4.6	213
133	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384.	2.0	6
134	The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition. Blood, 2016, 128, 1138-1138.	1.4	2
135	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. Blood, 2016, 128, 2065-2065.	1.4	1
136	Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function. Blood, 2016, 128, 2066-2066.	1.4	2
137	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. Blood, 2016, 128, 3266-3266.	1.4	1
138	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. Blood, 2016, 128, 3278-3278.	1.4	2
139	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. Blood, 2016, 128, 3304-3304.	1.4	3
140	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood, 2016, 128, 377-377.	1.4	1
141	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. Blood, 2016, 128, 4431-4431.	1.4	8
142	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood, 2016, 128, 4516-4516.	1.4	8
143	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. Blood, 2016, 128, 117-117.	1.4	1
144	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. Blood, 2016, 128, 2064-2064.	1.4	0

#	Article	IF	Citations
145	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. Blood, 2016, 128, 4416-4416.	1.4	1
146	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. Blood, 2016, 128, 4438-4438.	1.4	0
147	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. Blood, 2016, 128, 115-115.	1.4	2
148	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood, 2015, 125, 3756-3759.	1.4	41
149	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	3.5	44
150	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 30408-30419.	1.8	49
151	Patient-reported Outcomes for Multicentric Castlemanâ€™s Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient, 2015, 8, 207-216.	2.7	18
152	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clinical Cancer Research, 2015, 21, 4294-4304.	7.0	75
153	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. Blood, 2015, 126, 1806-1806.	1.4	2
154	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. Blood, 2015, 126, 1808-1808.	1.4	2
155	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). Blood, 2015, 126, 1843-1843.	1.4	1
156	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. Blood, 2015, 126, 20-20.	1.4	7
157	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	1.4	2
158	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Blood, 2015, 126, 369-369.	1.4	1
159	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. Blood, 2015, 126, 372-372.	1.4	1
160	Treatment of Castleman Disease. , 2015, 12, .		0
161	Impact of total therapies on clinical outcome of myeloma stratified by risk and molecular subgroups.. Journal of Clinical Oncology, 2015, 33, 8586-8586.	1.6	0
162	Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts). Blood, 2015, 126, 1997-1997.	1.4	0

#	Article	IF	Citations
163	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. Blood, 2015, 126, 724-724.	1.4	0
164	Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma. Blood, 2015, 126, 2982-2982.	1.4	0
165	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. Blood, 2015, 126, 4173-4173.	1.4	0
166	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. Blood, 2015, 126, 3181-3181.	1.4	2
167	Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma. Blood, 2015, 126, 2990-2990.	1.4	0
168	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	1.4	1
169	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 5395-5395.	1.4	0
170	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	1.4	0
171	Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. Blood, 2015, 126, 1777-1777.	1.4	23
172	Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2014, 2014, 15.	2.7	26
173	A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 134-135.	3.0	1
174	Siltuximab for multicentric Castleman disease. Expert Review of Hematology, 2014, 7, 545-557.	2.2	14
175	Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 211-214.	0.4	46
176	Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the Seventh Decade of Life. Journal of Molecular Diagnostics, 2014, 16, 68-74.	2.8	35
177	HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood, 2014, 123, 2924-2933.	1.4	259
178	Optimizing the treatment of multiple myeloma. Nature Reviews Clinical Oncology, 2014, 11, 686-688.	27.6	0
179	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 966-974.	10.7	345
180	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood, 2014, 124, 2051-2060.	1.4	26

#	Article	IF	Citations
181	The future of autologous stem cell transplantation in myeloma. Blood, 2014, 124, 328-333.	1.4	40
182	Engineering more efficacious antibody therapy for myeloma. Blood, 2014, 123, 3062-3063.	1.4	2
183	Curing myeloma at last: defining criteria and providing the evidence. Blood, 2014, 124, 3043-3051.	1.4	194
184	Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4). Blood, 2014, 124, 1199-1199.	1.4	4
185	Curing Multiple Myeloma (MM) with Total Therapy (TT). Blood, 2014, 124, 195-195.	1.4	3
186	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 2128-2128.	1.4	1
187	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. Blood, 2014, 124, 3409-3409.	1.4	5
188	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. Blood, 2014, 124, 3418-3418.	1.4	3
189	Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies. Blood, 2014, 124, 4464-4464.	1.4	1
190	Superior Restoration of Health with Siltuximab Among Multicentric Castlemanâ€™s Disease Patients When Measured By SF-36. Blood, 2014, 124, 4469-4469.	1.4	1
191	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. Blood, 2014, 124, 4775-4775.	1.4	4
192	HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review. Blood, 2014, 124, 4861-4861.	1.4	4
193	Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma. Blood, 2014, 124, 725-725.	1.4	1
194	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.	1.4	0
195	ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis. Blood, 2014, 124, 2102-2102.	1.4	1
196	Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study. Blood, 2014, 124, 2121-2121.	1.4	0
197	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. Blood, 2014, 124, 3407-3407.	1.4	0
198	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. Blood, 2014, 124, 5770-5770.	1.4	0

#	Article	IF	Citations
199	A Phase I, Open-Label Study of Siltuximab, an Antiâ€"IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research, 2013, 19, 3659-3670.	7.0	180
200	Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood, 2013, 121, 1819-1823.	1.4	181
201	Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels. PLoS ONE, 2013, 8, e54610.	2.5	44
202	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castlemanâ€™s Disease. Blood, 2013, 122, 505-505.	1.4	7
203	Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol. Blood, 2013, 122, 3137-3137.	1.4	0
204	MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. Blood, 2013, 122, 281-281.	1.4	1
205	Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival. Blood, 2013, 122, 1911-1911.	1.4	2
206	Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity. Blood, 2013, 122, 5389-5389.	1.4	0
207	Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5. Blood, 2012, 120, 193-193.	1.4	1
208	Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12â^¼23 Amplification. Blood, 2012, 120, 3983-3983.	1.4	1
209	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 579-579.	1.4	2
210	Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castlemanâ€™s disease.. Journal of Clinical Oncology, 2012, 30, TPS8117-TPS8117.	1.6	1
211	Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms. Blood, 2012, 120, 4020-4020.	1.4	0
212	Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up. Blood, 2012, 120, 1458-1458.	1.4	7
213	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. Blood, 2012, 120, 2933-2933.	1.4	0
214	Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3). Blood, 2012, 120, 195-195.	1.4	0
215	Prognostic Significance of DNA/Cig Flow Cytometry Assay in the â€˜eraâ€•of Novel Therapies in Multiple Myeloma (MM).. Blood, 2012, 120, 2918-2918.	1.4	6
216	Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups. Blood, 2012, 120, 1962-1962.	1.4	0

#	Article	IF	Citations
217	Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,. Blood, 2011, 118, 3941-3941.	1.4	0
218	Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC). Blood, 2011, 118, 298-298.	1.4	10
219	Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis. Blood, 2011, 118, 884-884.	1.4	6
220	Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma. Blood, 2011, 118, 2918-2918.	1.4	8
221	Superior results of Total Therapy 3 (2003-33) in gene expression profilingâ€"defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood, 2010, 115, 4168-4173.	1.4	196
222	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, 2010, 116, 1220-1227.	1.4	100
223	Siltuximab, a Novel Antiâ€"Interleukin-6 Monoclonal Antibody, for Castleman's Disease. Journal of Clinical Oncology, 2010, 28, 3701-3708.	1.6	195
224	Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms. Journal of Clinical Oncology, 2010, 28, 3023-3027.	1.6	39
225	Reply to J.C. Regelink et al. Journal of Clinical Oncology, 2010, 28, e744-e745.	1.6	0
226	Light-chain MGUS: implications for clinical practice. Lancet, The, 2010, 375, 1670-1671.	13.7	6
227	Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B. Blood, 2010, 116, 368-368.	1.4	4
228	Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM). Blood, 2010, 116, 1969-1969.	1.4	0
229	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.. Blood, 2010, 116, 1356-1356.	1.4	0
230	Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clinical Advances in Hematology and Oncology, 2010, 8, 486-98.	0.3	112
231	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 2009, 8, 2616-2624.	4.1	161
232	Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.. Blood, 2009, 114, 744-744.	1.4	7
233	High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2, A Master Regulator of Mirna Maturation and B-Cell Development.. Blood, 2009, 114, 1804-1804.	1.4	0
234	Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?. Nature Clinical Practice Oncology, 2008, 5, 70-71.	4.3	1

#	Article	IF	Citations
235	First thalidomide clinical trial in multiple myeloma: a decade. Blood, 2008, 112, 1035-1038.	1.4	47
236	Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients. Blood, 2008, 112, 667-667.	1.4	4
237	Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy. Blood, 2008, 112, 733-733.	1.4	10
238	Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. Journal of Clinical Oncology, 2007, 25, 1121-1128.	1.6	369
239	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research, 2007, 13, 7073-7079.	7.0	99
240	Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System. Clinical Cancer Research, 2007, 13, 1353-1355.	7.0	19
241	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood, 2007, 109, 1692-1700.	1.4	328
242	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 2007, 109, 2276-2284.	1.4	831
243	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 2007, 136, 393-399.	2.5	63
244	Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.. Blood, 2007, 110, 5012-5012.	1.4	0
245	The molecular classification of multiple myeloma. Blood, 2006, 108, 2020-2028.	1.4	997
246	NY-ESO-1 immunotherapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 2037-2048.	1.3	29
247	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood, 2006, 107, 2633-2638.	1.4	129
248	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 2006, 135, 158-164.	2.5	155
249	A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. Blood, 2006, 108, 111-111.	1.4	5
250	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. Blood, 2006, 108, 3393-3393.	1.4	1
251	Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of Myeloma.. Blood, 2006, 108, 3498-3498.	1.4	1
252	Con: allogeneic transplantation in multiple myeloma. Clinical Advances in Hematology and Oncology, 2006, 4, 391-4.	0.3	0

#	Article	IF	Citations
253	NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 2005, 105, 3939-3944.	1.4	173
254	Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).. Blood, 2005, 106, 3392-3392.	1.4	1
255	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.. Blood, 2005, 106, 423-423.	1.4	6
256	Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.. Blood, 2005, 106, 1981-1981.	1.4	0
257	Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.. Blood, 2005, 106, 1152-1152.	1.4	0
258	The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.. Blood, 2005, 106, 1157-1157.	1.4	1
259	Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs â€œDiscontinuousâ€•Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).. Blood, 2005, 106, 1153-1153.	1.4	0
260	Protective Effect of VELCADEÂ® on Thalidomide-Associated Deep Vein Thrombosis (DVT).. Blood, 2004, 104, 4914-4914.	1.4	8
261	Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.. Blood, 2004, 104, 77-77.	1.4	18
262	Addition of Bortezomib (Velcadeâ„¢) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. Blood, 2004, 104, 929-929.	1.4	12
263	NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.. Blood, 2004, 104, 2454-2454.	1.4	0
264	KIR-LIGAND Mismatched Natural Killer Cells Effectively Kill Primary Myeloma and Myeloma Cell Lines.. Blood, 2004, 104, 2449-2449.	1.4	0
265	NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.. Blood, 2004, 104, 2464-2464.	1.4	0